<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671970</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000220</org_study_id>
    <nct_id>NCT00671970</nct_id>
  </id_info>
  <brief_title>Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)</brief_title>
  <official_title>Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To estimate 6-month progression free survival probability of pts w recurrent malignant
      gliomas treated w erlotinib + bevacizumab.

      Secondary Objectives:

      To evaluate safety &amp; tolerability of erlotinib + bevacizumab among pts w recurrent malignant
      gliomas To evaluate radiographic response of pts w recurrent malignant gliomas treated w
      erlotinib + bevacizumab To evaluate pharmacokinetics of erlotinib when administered to pts w
      recurrent malignant gliomas; &amp; to examine relationship of clinical response to Epidermal
      Growth Factor (EGFR) expression, amplification, &amp; v-III mutation, phosphatase and tensin
      homolog (PTEN) expression, vascular endothelial growth factor (VEGF) expression, vascular
      endothelial growth factor receptor 2 (VEGFR-2) &amp; phosphorylated protein kinase B (PKB/Akt) in
      archival tumor samples
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploratory, Phase II study designed to assess anti-tumor activity of combinatorial regimen
      consisting of erlotinib + bevacizumab among pts w recurrent malignant glioma. Signal
      transduction inhibitors, such as erlotinib, as well as anti-angiogenic agents, such as
      bevacizumab, are expected to exert a cytostatic anti-tumor effect. Primary endpoint of study
      is probability of progression-free survival at 6 months. An important secondary objective is
      to further assess the safety of erlotinib + bevacizumab for pts w RMG. Pharmacokinetic
      studies included in protocol will evaluate impact of enzyme-inducing anti-epileptic drugs
      (EIAEDs) on metabolism of erlotinib.

      If study demonstrates that combo regimen of erlotinib + bevacizumab is associated w
      encouraging anti-tumor activity among pts w recurrent malignant glioma (RMG), further
      assessment of regimen in additional ph II &amp; possibly ph III studies, will be considered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Month Progression-free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of patients alive and progression free at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response</measure>
    <time_frame>Patients were followed for the duration of the study, with a median follow-up of 103 weeks for grade III participants and 141.8 weeks for grade IV participants</time_frame>
    <description>The number of participants with complete or partial response as determined by the following criteria:
Complete response (CR): Disappearance of all enhancing tumor on contrast enhanced MRI scan. Patient must be off steroids or only on adrenal maintenance doses.
Partial response (PR): Greater than or equal to a 50% reduction in the size (products of the largest perpendicular diameters) for all enhancing lesions. No new lesions may arise. Steroids must be stable or decreasing dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Erlotinib: Cmax</measure>
    <time_frame>Day 1 and 42 of Dosing Erlotinib</time_frame>
    <description>Day 1 and Day 42 of Dosing Erlotinib in Cycle 1: Maximum Concentration (ng/mL) (Cmax) for subjects receiving 500 mg (Enzyme-Inducing Anti-epileptic Drug, EIAED) or 200 mg (non-EIAED) Erlotinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Erlotinib: AUC</measure>
    <time_frame>Day 1 and 42 of Dosing Erlotinib</time_frame>
    <description>Day 1 and Day 42 of Dosing Erlotinib in Cycle 1: Area under the Curve (ng/mL.h) (AUC) for subjects receiving 500 mg (Enzyme-Inducing Anti-epileptic Drug, EIAED) or 200 mg (non-EIAED) Erlotinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Biomarkers and One-year Survival - Epidermal Growth Factor (EGFR)</measure>
    <time_frame>1 year</time_frame>
    <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Biomarkers and One-year Survival - EGFR vIII</measure>
    <time_frame>1 year</time_frame>
    <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Biomarkers and One-year Survival - Phosphatase and Tensin Homologue (PTEN)</measure>
    <time_frame>1 year</time_frame>
    <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Biomarkers and One-year Survival - Phosphorylated Protein Kinase B (pAKT)</measure>
    <time_frame>1 year</time_frame>
    <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Biomarkers and One-year Survival - Phosphorylated Mitogen-activated Protein Kinase (pMAPK)</measure>
    <time_frame>1 year</time_frame>
    <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Biomarkers and One-year Survival - Vascular Endothelial Growth Factor (VEGF)</measure>
    <time_frame>1 year</time_frame>
    <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry (IHC) for biomarkers. The IHC expression score is the product of the percentage of cancer cells positive for VEGF multiplied by the overall intensity of staining, ranging from 0 to 3+. This produces a score ranging from 0 to 300.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Biomarkers and One-year Survival - VEGFR-2</measure>
    <time_frame>1 year</time_frame>
    <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry (IHC) for biomarkers. The IHC score is the product of the percentage of cancer cells positive for VEGFR-2 multiplied by the overall intensity of staining, ranging from 0 to 3+. This produces a score ranging from 0 to 300.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab + Erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and Erlotinib</intervention_name>
    <description>Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs &amp; 500 mg/day for pts on EIAEDs.
It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.</description>
    <arm_group_label>Bevacizumab + Erlotinib</arm_group_label>
    <other_name>Bevacizumab</other_name>
    <other_name>Erlotitnib</other_name>
    <other_name>Avastin</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pts have histologically confirmed diagnosis of recurrent/progressive WHO gr III &amp; IV
             MG &amp; meet following inclusion criteria:

          -  Age &gt;18 yrs

          -  Interval of &gt;4 wks since prior surgery

          -  Interval of &gt;4 wks since prior external beam radiation therapy (XRT) or chemo, unless
             there is unequivocal evidence of progressive disease &amp; pts have recovered from all
             anticipated toxicity of most recent therapy

          -  Karnofsky performance status score &gt;60

          -  Hematocrit &gt; 29 percent, absolute neutrophil count (ANC) &gt;1,500 cells/microliter,
             platelets &gt;100,000 cells/microliter

          -  Serum creatinine &lt;.5mg/dl, blood urea nitrogen (BUN) &lt;25 mg/dl, serum glutamate
             oxaloacetate transaminase (SGOT) &amp; bilirubin &lt;1.5 x upper limit of normal (ULN)

          -  For pts on corticosteroids, they have been on stable dose for 1 wk prior to entry

          -  Pts have had prior bevacizumab are eligible however interval of &gt;6 wks must have
             elapsed since their last dose

          -  Signed informed consent approved by Institutional Review Board (IRB) prior to patient
             entry;

          -  If sexually active, pts must agree to take contraceptive measures for duration of
             treatments

        Exclusion Criteria:

          -  Prior therapy w either bevacizumab/EGFR-directed agents

          -  &gt;3 prior recurrences

          -  Pregnancy/breast feeding

          -  Co-medication w immuno-suppressive agents other than corticosteroids including but not
             limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil

          -  Evidence of central nervous system (CNS) hemorrhage on baseline MRI on CT scan

          -  Pts who require therapeutic anti-coagulation

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring IV antibiotics &amp; psychiatric illness/social situations that would
             limit compliance w study requirements, or disorders associated w significant
             immunocompromised state

          -  Pts w another primary malignancy that has required treatment within past year

          -  Pts w acute/chronic renal insufficiency/those w acute renal insufficiency of any
             severity due to hepato-renal syndrome/in peri-operative liver transplantation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Reardon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.duke.edu/btc/</url>
    <description>The Preston Robert Tisch Brain Tumor Center at DUKE</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>December 28, 2012</results_first_submitted>
  <results_first_submitted_qc>March 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2013</results_first_posted>
  <last_update_submitted>March 29, 2013</last_update_submitted>
  <last_update_submitted_qc>March 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Gliosarcoma</keyword>
  <keyword>Recurrent MG</keyword>
  <keyword>Malignant glioma</keyword>
  <keyword>Glioma</keyword>
  <keyword>Glioblastoma multiforme (GBM)</keyword>
  <keyword>GBM</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Anaplastic astrocytoma</keyword>
  <keyword>Anaplastic oligodendroglioma</keyword>
  <keyword>Anaplastic oligoastrocytoma</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Tarceva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Open for recruitment from February 2007 to May 2008. Subjects recruited in the Preston Robert Tisch Brian Tumor Center at Duke University Medical Center (DUMC).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>WHO Grade III</title>
          <description>WHO Grade III Malignant Glioma
Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs &amp; 500 mg/day for pts on EIAEDs.</description>
        </group>
        <group group_id="P2">
          <title>WHO Grade IV</title>
          <description>WHO Grade IV Malignant Glioma
Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs &amp; 500 mg/day for pts on EIAEDs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Who Grade III</title>
          <description>Who Grade III Malignant Glioma</description>
        </group>
        <group group_id="B2">
          <title>WHO Grade IV</title>
          <description>WHO Grade IV Malignant Glioma</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="12.8" lower_limit="26.0" upper_limit="72.2"/>
                    <measurement group_id="B2" value="51.5" spread="13.4" lower_limit="24.1" upper_limit="70.4"/>
                    <measurement group_id="B3" value="49.98" spread="13.05" lower_limit="24.1" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6 Month Progression-free Survival</title>
        <description>The proportion of patients alive and progression free at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Who Grade III</title>
            <description>Who Grade III Malignant Glioma</description>
          </group>
          <group group_id="O2">
            <title>WHO Grade IV</title>
            <description>WHO Grade IV Malignant Glioma</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Progression-free Survival</title>
          <description>The proportion of patients alive and progression free at 6 months</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".438" lower_limit=".265" upper_limit=".598"/>
                    <measurement group_id="O2" value=".292" lower_limit=".130" upper_limit=".476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Response</title>
        <description>The number of participants with complete or partial response as determined by the following criteria:
Complete response (CR): Disappearance of all enhancing tumor on contrast enhanced MRI scan. Patient must be off steroids or only on adrenal maintenance doses.
Partial response (PR): Greater than or equal to a 50% reduction in the size (products of the largest perpendicular diameters) for all enhancing lesions. No new lesions may arise. Steroids must be stable or decreasing dose.</description>
        <time_frame>Patients were followed for the duration of the study, with a median follow-up of 103 weeks for grade III participants and 141.8 weeks for grade IV participants</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Who Grade III</title>
            <description>Who Grade III Malignant Glioma</description>
          </group>
          <group group_id="O2">
            <title>WHO Grade IV</title>
            <description>WHO Grade IV Malignant Glioma</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Response</title>
          <description>The number of participants with complete or partial response as determined by the following criteria:
Complete response (CR): Disappearance of all enhancing tumor on contrast enhanced MRI scan. Patient must be off steroids or only on adrenal maintenance doses.
Partial response (PR): Greater than or equal to a 50% reduction in the size (products of the largest perpendicular diameters) for all enhancing lesions. No new lesions may arise. Steroids must be stable or decreasing dose.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Erlotinib: Cmax</title>
        <description>Day 1 and Day 42 of Dosing Erlotinib in Cycle 1: Maximum Concentration (ng/mL) (Cmax) for subjects receiving 500 mg (Enzyme-Inducing Anti-epileptic Drug, EIAED) or 200 mg (non-EIAED) Erlotinib</description>
        <time_frame>Day 1 and 42 of Dosing Erlotinib</time_frame>
        <population>22 WHO Grade IV participants were available for pharmacokinetics studies of erlotinib</population>
        <group_list>
          <group group_id="O1">
            <title>WHO Grade IV</title>
            <description>WHO Grade IV Malignant Glioma</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Erlotinib: Cmax</title>
          <description>Day 1 and Day 42 of Dosing Erlotinib in Cycle 1: Maximum Concentration (ng/mL) (Cmax) for subjects receiving 500 mg (Enzyme-Inducing Anti-epileptic Drug, EIAED) or 200 mg (non-EIAED) Erlotinib</description>
          <population>22 WHO Grade IV participants were available for pharmacokinetics studies of erlotinib</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1 Cmax{ng/ml}200mg n=12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794" lower_limit="524" upper_limit="2200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 Cmax{ng/ml}500mg n=10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1323" lower_limit="317" upper_limit="2990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day42 Cmax{ng/ml}200mg n=9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1320" lower_limit="525" upper_limit="2940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day42 Cmax{ng/ml}500mg n=9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1400" lower_limit="716" upper_limit="3955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Erlotinib: AUC</title>
        <description>Day 1 and Day 42 of Dosing Erlotinib in Cycle 1: Area under the Curve (ng/mL.h) (AUC) for subjects receiving 500 mg (Enzyme-Inducing Anti-epileptic Drug, EIAED) or 200 mg (non-EIAED) Erlotinib</description>
        <time_frame>Day 1 and 42 of Dosing Erlotinib</time_frame>
        <population>22 WHO Grade IV participants were available for pharmacokinetics studies of erlotinib</population>
        <group_list>
          <group group_id="O1">
            <title>WHO Grade IV</title>
            <description>WHO Grade IV Malignant Glioma</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Erlotinib: AUC</title>
          <description>Day 1 and Day 42 of Dosing Erlotinib in Cycle 1: Area under the Curve (ng/mL.h) (AUC) for subjects receiving 500 mg (Enzyme-Inducing Anti-epileptic Drug, EIAED) or 200 mg (non-EIAED) Erlotinib</description>
          <population>22 WHO Grade IV participants were available for pharmacokinetics studies of erlotinib</population>
          <units>ng/ml.h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1 AUC 0-24{ng/ml.h} 200mg n=12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11072" lower_limit="7850" upper_limit="30029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 AUC 0-24{ng/ml.h} 500mg n=10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15611" lower_limit="5295" upper_limit="40110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day42 AUC 0-24{ng/ml.h}200mg n=9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26072" lower_limit="8308" upper_limit="42878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day42 AUC 0-24{ng/ml.h}500mg n=9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21421" lower_limit="11680" upper_limit="55960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Biomarkers and One-year Survival - Epidermal Growth Factor (EGFR)</title>
        <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
        <time_frame>1 year</time_frame>
        <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. One tumor had an insufficient measurement for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Positive Expression</title>
            <description>EGFR positive expression</description>
          </group>
          <group group_id="O2">
            <title>Negative Expression</title>
            <description>EGFR negative expression</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Biomarkers and One-year Survival - Epidermal Growth Factor (EGFR)</title>
          <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
          <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. One tumor had an insufficient measurement for analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Biomarkers and One-year Survival - EGFR vIII</title>
        <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
        <time_frame>1 year</time_frame>
        <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive Expression</title>
            <description>EGFR vIII positive expression</description>
          </group>
          <group group_id="O2">
            <title>Negative Expression</title>
            <description>EGFR vIII negative expression</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Biomarkers and One-year Survival - EGFR vIII</title>
          <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
          <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.613</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Biomarkers and One-year Survival - Phosphatase and Tensin Homologue (PTEN)</title>
        <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
        <time_frame>1 year</time_frame>
        <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. One tumor had an insufficient measurement for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Intact</title>
            <description>PTEN Intact</description>
          </group>
          <group group_id="O2">
            <title>Loss</title>
            <description>PTEN Loss</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Biomarkers and One-year Survival - Phosphatase and Tensin Homologue (PTEN)</title>
          <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
          <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. One tumor had an insufficient measurement for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Biomarkers and One-year Survival - Phosphorylated Protein Kinase B (pAKT)</title>
        <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
        <time_frame>1 year</time_frame>
        <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. Four tumors had an insufficient measurement for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive Expression</title>
            <description>pAKT positive expression</description>
          </group>
          <group group_id="O2">
            <title>Negative Expression</title>
            <description>pAKT negative expression</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Biomarkers and One-year Survival - Phosphorylated Protein Kinase B (pAKT)</title>
          <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
          <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. Four tumors had an insufficient measurement for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Biomarkers and One-year Survival - Phosphorylated Mitogen-activated Protein Kinase (pMAPK)</title>
        <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
        <time_frame>1 year</time_frame>
        <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. Six tumors had an insufficient measurement for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive Expression</title>
            <description>pMAPK positive expression</description>
          </group>
          <group group_id="O2">
            <title>Negative Expression</title>
            <description>pMAPK negative expression</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Biomarkers and One-year Survival - Phosphorylated Mitogen-activated Protein Kinase (pMAPK)</title>
          <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry for biomarkers.</description>
          <population>Tumors from 22 GBM participants were available to undergo immunohistochemical staining to identify potential biomarkers of response or survival benefit. Six tumors had an insufficient measurement for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Biomarkers and One-year Survival - Vascular Endothelial Growth Factor (VEGF)</title>
        <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry (IHC) for biomarkers. The IHC expression score is the product of the percentage of cancer cells positive for VEGF multiplied by the overall intensity of staining, ranging from 0 to 3+. This produces a score ranging from 0 to 300.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Survived At Least 1 Year</title>
            <description>Patients who survived at least 1 year</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Survived Less Than 1 Year</title>
            <description>Patients who survived less than 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Biomarkers and One-year Survival - Vascular Endothelial Growth Factor (VEGF)</title>
          <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry (IHC) for biomarkers. The IHC expression score is the product of the percentage of cancer cells positive for VEGF multiplied by the overall intensity of staining, ranging from 0 to 3+. This produces a score ranging from 0 to 300.</description>
          <units>IHC Expression Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="4" upper_limit="120"/>
                    <measurement group_id="O2" value="60" lower_limit="20" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.179</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Biomarkers and One-year Survival - VEGFR-2</title>
        <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry (IHC) for biomarkers. The IHC score is the product of the percentage of cancer cells positive for VEGFR-2 multiplied by the overall intensity of staining, ranging from 0 to 3+. This produces a score ranging from 0 to 300.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Survived At Least 1 Year</title>
            <description>Patients who survived at least 1 year</description>
          </group>
          <group group_id="O2">
            <title>Patients Who Survived Less Than 1 Year</title>
            <description>Patients who survived less than 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Biomarkers and One-year Survival - VEGFR-2</title>
          <description>Archival tumor samples from grade IV participants were examined by immunohistochemistry (IHC) for biomarkers. The IHC score is the product of the percentage of cancer cells positive for VEGFR-2 multiplied by the overall intensity of staining, ranging from 0 to 3+. This produces a score ranging from 0 to 300.</description>
          <units>IHC Expression Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="20" upper_limit="100"/>
                    <measurement group_id="O2" value="120" lower_limit="40" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The length of time that the subjects were receiving treatment and then 30 days after treatment termination.</time_frame>
      <desc>Adverse events were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, but were converted to CTCAE version 4.0 for entry into ClinicalTrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>All Patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dihiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Avascular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nervous system disorders-Other, specify: Visual Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Investigations-Other, specify: Total protein, low</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nervous system disorders-Other, specify: Mood Alteration, NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders-Other, specify: Sexual Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Reardon</name_or_title>
      <organization>Dana Farber Cancer Institute</organization>
      <phone>(617) 632-2166</phone>
      <email>David_Reardon@DFCI.HARVARD.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

